GrowBLOX Sciences Provides Update on its Grow and Dispensary Efforts in Nevada
LAS VEGAS, NV / ACCESSWIRE / December 17, 2014 / GrowBLOX Sciences, Inc., “GB Sciences” (OTCQB:GBLX), a company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize safe and consistent medicinal cannabis, is pleased to update its shareholders on its efforts to receive the necessary licenses to grow and dispense medical cannabis in Nevada.
We recently announced that we had received written notice from the Nevada Department of Health and Human Services approving the application of our subsidiary, GB Sciences Nevada LLC for a medical marijuana establishment (“MME”) cultivation facility, which is consistent with prior approvals the Company received from the City of Las Vegas and Clark County, Nevada. The Company is proceeding with architectural plans, business licensing and all the regulatory steps required to commence cultivation activities in the first half of 2015.
On Dec. 1, 2014, our subsidiary, GB Sciences Nevada LLC (“GBSN”), together with four other plaintiffs, filed a complaint against the State of Nevada, Department of Health and Human Services, Division of Public and Behavioral Health and several others. In addition, on December 5, 2014, GBSN filed an additional complaint against the State of Nevada, Division of Public and Behavioral Health of the Department of Health and Human Services; City of Las Vegas, Desert Aire Wellness llc; and Nuleaf ChV Dispensary, LLC.
Prior to filing these lawsuits, GBSN had submitted applications for MME dispensaries in Clark County and the City of Las Vegas. After a rigorous process, GBSN was approved and found suitable and qualified by both the County and the City. In the case of the City, the City Council voted 6-0-1 in favor of our application. We then submitted all approved applications to the State of Nevada.
Subsequent to Clark County and the City of Las Vegas approving GBSN and other applicants, several unsuccessful applicants nevertheless filed MME dispensary applications with the State of Nevada, without obtaining local approval. The State then issued provisional licenses to certain of these non-approved applicants, notwithstanding prior legislation, regulation and testimony that local approval, including use permits, are prerequisites for such applications to be deemed complete and suitable for ranking and licensure. In the absence of such local approvals, we believe that these applications should have been deemed incomplete and disqualified. We also believe that there is legal precedent for our views.
Accordingly, it is the Company’s position that the State acted improperly in issuing many of the provisional license notifications, and had it adhered to the legislation, the legislative intent and existing State and local regulations, GBSN would have received provisional State licenses for its applications in Clark County and the City of Las Vegas, as we ranked within the top 18 applicants in Clark County and top 12 applicants in the City of Las Vegas.
Although there can be no assurance that we will be successful in this litigation, we have been advised by counsel we have a strong case and should prevail on the merits.
We will keep our shareholders advised as to the outcome of this matter.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc. “GB Sciences” is a biopharmaceutical research and development company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
To learn more about GB Sciences, Inc., go to www.gbsciences.com.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: GrowBLOX Sciences, Inc.